Ikena™ Approach

We are pioneering the discovery and development of novel patient-directed oncology therapies across multiple molecular pathways relevant in tumor and immune cells.

At Ikena, we begin with the end in mind. We develop oncology therapies that are best for patients by understanding which patients are best suited for our therapies. We focus on subgroups of patients who will most benefit from our targeted oncology and immunotherapy drug candidates, ensuring that we can bring the right drug to the right patient. We live on the cutting edge of cancer research, having recently initiated targeted oncology programs in the Hippo pathway and the Ras-signaling pathway.
We have a proven track record, as a team, of developing a first-in-class portfolio of biomarker-driven therapies targeting key drivers of cancer progression, aimed at curing molecularly defined cancer patient populations.
advance novel oncology therapies
We pursue opportunities where we can use our discovery, translational, and development expertise to rapidly advance novel oncology therapies efficiently by developing clinical strategies with the highest probability for success.

Our discovery research engine utilizes a robust, multidisciplinary approach to elucidate promising targets across pathways in cancer cells and in immune cells, to understand mechanisms of action and the biology that drives disease, and to rapidly generate small molecule or biologics development candidates.

We perfect the art of translational research by deliberately connecting the scientific rationale from the lab into patient benefit in the clinic, moving quickly to a proof of concept (POC) while de-risking the program at every turn. Once in the clinic, we employ optimized trial designs that allow for rapid paths to clinical POC.

Our goal is to build a leading oncology research and development company with a validated patient-focused methodology, a proven track record for advancing first-in-class or best-in-class targeted oncology therapies and immunotherapies through optimized path to POC, and a roster of collaborations with top-tier strategic partners that accelerate bringing novel medicines to patients.

Explore the scientific research that supports our pipeline.